Press releases

03-May-2026
UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers
01-May-2026
UCB announces acquisition of IMIDomics’ Patient Insight Business, strengthening capabilities in immune-mediated inflammatory diseases (IMIDs)
30-Apr-2026
UCB’s General Meeting of Shareholders 2026
24-Apr-2026
Acquisition of own shares
17-Apr-2026
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science
17-Apr-2026
Acquisition of own shares
15-Apr-2026
UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting
10-Apr-2026
Acquisition of own shares
03-Apr-2026
Acquisition of own shares
31-Mar-2026
European Commission approves KYGEVVI[®]▼ (doxecitine and doxribtimine) as first and only treatment for Thymidine Kinase 2 Deficiency (TK2d)
27-Mar-2026
UCB announces new BIMZELX[®] (bimekizumab-bkzx) data at AAD showing durable symptom control throughout three years in hidradenitis suppurativa
27-Mar-2026
UCB presents new BIMZELX[®] (bimekizumab-bkzx) data at AAD demonstrating high rates of durable and complete skin clearance in moderate-to-severe plaque psoriasis
27-Mar-2026
Acquisition of own shares
27-Mar-2026
UCB Annual General Meeting of Shareholders 2026
26-Mar-2026
UCB receives positive CHMP opinion for new ZILBRYSQ[®]▼ (zilucoplan) pre-filled pen in EU for adults living with generalized myasthenia gravis
24-Mar-2026
UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs
20-Mar-2026
Acquisition of own shares
13-Mar-2026
Share Repurchase Program 2026 to cover UCB's Long Term Incentive Plans for employees
11-Mar-2026
BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50
03-Mar-2026
UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody
26-Feb-2026
Strong Execution Fueling Sustained Company Growth
04-Feb-2026
UCB showcases three-year hidradenitis suppurativa data at EHSF: BIMZELX[®]▼(bimekizumab) achieved inflammatory lesion resolution and substantial disease severity improvements
30-Jan-2026
KYGEVVI[®] (doxecitine and doxribtimine) recommended for approval in the European Union as treatment for Thymidine Kinase 2 Deficiency (TK2d)
13-Jan-2026
Innovation and Execution Power UCB’s Success

Press releases

UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers

UCB announces acquisition of IMIDomics’ Patient Insight Business, strengthening capabilities in immune-mediated inflammatory diseases (IMIDs)

UCB’s General Meeting of Shareholders 2026

Acquisition of own shares

UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science

Acquisition of own shares

UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting

Acquisition of own shares

Acquisition of own shares

European Commission approves KYGEVVI[®]▼ (doxecitine and doxribtimine) as first and only treatment for Thymidine Kinase 2 Deficiency (TK2d)

UCB announces new BIMZELX[®] (bimekizumab-bkzx) data at AAD showing durable symptom control throughout three years in hidradenitis suppurativa

UCB presents new BIMZELX[®] (bimekizumab-bkzx) data at AAD demonstrating high rates of durable and complete skin clearance in moderate-to-severe plaque psoriasis

Acquisition of own shares

UCB Annual General Meeting of Shareholders 2026

UCB receives positive CHMP opinion for new ZILBRYSQ[®]▼ (zilucoplan) pre-filled pen in EU for adults living with generalized myasthenia gravis

UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs

Acquisition of own shares

Share Repurchase Program 2026 to cover UCB's Long Term Incentive Plans for employees

BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50

UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody

Strong Execution Fueling Sustained Company Growth

UCB showcases three-year hidradenitis suppurativa data at EHSF: BIMZELX[®]▼(bimekizumab) achieved inflammatory lesion resolution and substantial disease severity improvements

KYGEVVI[®] (doxecitine and doxribtimine) recommended for approval in the European Union as treatment for Thymidine Kinase 2 Deficiency (TK2d)

Innovation and Execution Power UCB’s Success